In these late-postmenopausal women with LS osteopenia and > or = 1 additional risk factor or hip osteopenia , 24-month treatment with risedronate 5 mg/d was associated with the prevention of bone loss at the spine and hip ( based on significant increases in BMD in the LS and total proximal Fem ) and reduced bone resorption ( based on significantly reduced concen - trations of uNTx and sBAP ) and was well tolerated .
